Stephen F. Betz, Chief Scientific Officer at Crinetics Pharmaceuticals, Inc. (CRNX), sold 11,249 shares at $34.17 ($385K) on 2025-03-19, disclosed to the SEC on 2025-03-21.
Scheduled sale ($385k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.17 | 5,479 | $187K | 48.7% |
| 2 | $34.17 | 5,479 | $187K | 48.7% |
| 3 | $34.83 | 291 | $10K | 2.6% |
| Total | $34.19 avg | 11,249 | $385K | 100% |
| Filing → |
| CRNX | SELL | 2024-09-12 | $107K | — | Filing → |
| CRNX | SELL | 2024-08-28 | $160K | — | Filing → |
| CRNX | SELL | 2024-08-14 | $143K | — | Filing → |